item management s discussion and analysis of financial condition and results of operations results of operations overview since its inception through december   the company has incurred ongoing losses from operations and has cumulative losses as of december  totaling  to date  the company has not recorded any revenue from the sale of products 
revenue recorded through december  was earned in connection with contract research and the granting of certain short term rights 
the company expects to remain in the development stage for the foreseeable future and accordingly  expects to continue to incur substantial losses 
years ended december  and no revenues were earned in the years ended december  and research and development expenses were  in  as compared with  for the year ended december  the decrease reflects overall reduced research and clinical trial activity levels partially offset by restructuring costs incurred as a result of a corporate downsizing 
general and administrative expenses were  in  as compared with  for the year ended december  the decrease is due primarily to increased corporate activity and restructuring costs in the first half of offset by reduced corporate activity in the second half of after the restructuring occurred 
net interest income was  in  as compared with  for the year ended december  the decrease is due to a lower balance of cash available for investment 
the net loss was  in  as compared with  for the year ended december  the net loss per share decreased from for the year ended december  to for the year ended december  this reflects the recent decrease in research and development activity levels partially offset by restructuring costs incurred as a result of a corporate downsizing 
in april  the company announced disappointing results from the phase iii trial of myloral r  its product for multiple sclerosis 
very soon thereafter  the company also announced a corporate downsizing by eliminating positions directly related to the myloral program and an increased focus of resources on the development of colloral for rheumatoid arthritis 
the company recorded a charge during the second quarter of of approximately  relating primarily to employee severance costs and costs associated with terminating myloral manufacturing and clinical trial functions 
this estimated charge was adjusted to  during the third quarter of to reflect actual costs incurred 
in may  the company announced preliminary results from two phase ii trials of colloral for rheumatoid arthritis 
both trials demonstrated positive trends for colloral  although statistical significance was not demonstrated versus placebo 
a further restructuring plan was announced in june  to further focus the company s efforts to the clinical program for colloral 
this resulted in a further workforce reduction of positions 
the company recorded a charge during the second quarter of of approximately  relating to employee severance  costs associated with vacating leased space and equipment disposal and write offs 
this estimated charge was adjusted to  during the third quarter of to reflect the sublease of  square feet of space and actual costs incurred 
years ended december  and revenue for the year ended december  of  represents fees paid by a japanese pharmaceutical company for a short term exclusive right among japanese companies to review the results of the phase ii dosing study of colloral 
no revenue was earned in the year ended december  research and development expenses were  in  as compared with  for the year ended december  the increase is due to the advancement of clinical trial activity and the scale up of manufacturing capacity 
general and administrative expenses were  in  as compared with  for the year ended december  the increase is due primary to personnel costs and the timing of corporate activity 
net interest income was  in  as compared with  for the year ended december  the increase is due to a higher balance of cash available for investment 
the net loss was  in  as compared with  for the year ended december  the increase reflects the continued growth in the company s development activities 
the net loss per share increased from for the year ended december  to for the year ended december  due to an increase in the net loss partially offset by an increase in weighted average shares outstanding 
liquidity and capital resources the company s needs for funds have increased from period to period as it has increased the scope of its research and development activities although its needs have been reduced as a result of downsizing which occurred during the first half of since inception  the company has funded these needs almost entirely through sales of its equity securities 
the company s working capital and capital requirements will depend on numerous factors  including the progress of the company s research and development activities  the level of resources that the company devotes to the development  clinical  regulatory and marketing aspects of its products  the extent to which it proceeds by means of collaborative relationships with pharmaceutical companies and its competitive environment 
based upon its current plans  the company believes that current cash and marketable securities and the interest earned from the investment thereof will be sufficient to meet the company s operating expenses and capital requirements through the phase iii clinical program of colloral 
at the appropriate time  the company intends to seek additional funding through public or private equity or debt financings  collaborative arrangements with pharmaceutical companies or from other sources 
if additional funds are necessary but not available  the company will have to reduce certain areas of research  product development  manufacturing or marketing activity  or otherwise modify its business strategy  and its business will be materially adversely affected 
in order to preserve principal and maintain liquidity  the company s funds are invested in us treasury obligations and other short term instruments 
as of december   the company s cash and cash equivalents and marketable securities totaled  current liabilities at december  were 
